CompletedNot Applicable

Immunity Against AAV in Crigler Najjar Patient

France49 participantsStarted 2014-11

Plain-language summary

The proposed research protocol aims at addressing these points by pre-screening CN patients for their AAV serology in link with their medical history and current medical status. A first objective is to assess the presence of neutralizing AAV antibodies in the serum of CN patients.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The patient has a Crigler-Najjar syndrome * The molecular diagnosis has been confirmed by UGT1A1 gene DNA sequencing Exclusion criteria: * The patient is liver transplanted * The patient is suffering from severe associated pathologies precluding further enrolment in a future interventional clinical study

What they're measuring

To assess the presence of neutralizing AAV antibodies in the serum of CN patients

Timeframe: 1 day visit

Trial details

NCT IDNCT02302690

SponsorGenethon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-06

View on ClinicalTrials.gov More Crigler Najjar Syndrome trials